ARTICLE | Distillery Therapeutics

Therapeutics: CD19; CD28; tumor necrosis factor receptor superfamily member 9 (4-1BB; TNFRSF9; CD137)

October 29, 2015 7:00 AM UTC

Mouse studies suggest T cells engineered to express an anti-CD19/CD28 chimeric antigen receptor (CAR) and full-length 4-1BB could help treat ALL. T cells were transformed with one of two constructs: a...